BRCA1 was identified as a gene frequently mutated in familial breast and ovarian cancer. Surprisingly, however, the frequency of BRCA1 mutation in sporadic cancer is very low. We have shown that while BRCA1 dysfunction may be more broadly involved in breast tumorigenesis than previously thought, and that defects in the nuclear translocation of BRCA1 protein may be a common determinant of breast cancer. Thus, we propose to investigate the molecular basis by which BRCA1 is translocated to the nucleus in normal cells and how the malfunction of this mechanism in breast epithelial cells leads to cancer.
Our specific Aims are: (1) To confirm that a defective transportation process is a common cause of BRCA1 mislocation in advanced breast tumor cells, by examining the localization of exogenous, epitope- tagged, wild-type BRCA1 in normal cells and breast tumor lines by immunostaining and cell fractionation. We will also determine the nuclear localization signal (NLS) motif of BRCA1 by assessing the ability of mutants of the putative BRCA1 NLS motifs to translocate correctly to the nucleus. (2) To identify specific BRCA1 interacting proteins that are required for its correct localization, using the complementary methods of yeast two-hybrid screening and co- immunoprecipitation. (3) To test whether expression of proteins identified in aim 2 that are mutated in advanced breast cancer cell lines can rescue the transport of endogenous or ectopically expressed BRCA1 protein into the nucleus of breast tumor cells. (4) To assess the role of the identified genes in breast cancer development and progression. To do this, we will develop both immunostaining procedures and PCR-based SSCP assays to screen both premalignant breast lesions and primary invasive tumor specimens from the tumor Bank and Data Network Core, so as to establish any potential correlation between tumor development, prognosis, and mutation of the BRCA1 nuclear-transport protein. We have already made significant progress with the initial aims of this project. Results obtained from this investigation should provide considerable insight into the mechanism of BRCA1 transport and, in so doing, may identify other genes important in breast cancer. By combining both novel basic research and clinical correlation, we hope to provide information that will lead to better screening, prognostic assessment, and treatment of the most common fatal disease of women in developed countries.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA030195-21S1
Application #
6600435
Study Section
Project Start
2001-08-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Gutierrez, Carolina; Schiff, Rachel (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55-62
Wang, Yen-Chao; Morrison, Gladys; Gillihan, Ryan et al. (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121

Showing the most recent 10 out of 260 publications